ENTX: Entera Bio Ltd. Stock

by  •  • Comments Off on ENTX: Entera Bio Ltd. Stock

SIC 2836 – Biological Products, Except Diagnostic Substances (Biotech)

Valuation
Market Cap ($M) 91.07
Enterprise Value ($M) 78.50
Book Value ($M) 19.38
Book Value / Share 0.43
Price / Book 4.70
NCAV ($M) 19.00
NCAV / Share 0.42
Price / NCAV 4.79

Profitability (mra)
Return on Invested Capital (ROIC) -0.51
Return on Assets (ROA) -0.99
Return on Equity (ROE) -1.14

Liquidity (mrq)
Quick Ratio 13.07
Current Ratio 13.07

Balance Sheet (mrq) ($M)
Current Assets 21.22
Assets 21.60
Liabilities 2.22
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.18
Operating Income -9.59
Net Income -9.54
Earnings Per Share Diluted n/a
Earnings Per Share Basic n/a

Cash Flow Statement (mra) ($M)
Cash From Operations -6.82
Cash from Investing -0.00
Cash from Financing 4.48

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
04-02 13G Opko Health, Inc. 8.10
01-06 13G Point72 Asset Management, L.P. 6.80
11-20 13G/A Knoll Capital Management, LLC 15.00 51.52
08-20 13G/A Centillion Fund Inc. 6.70 0.00

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2025-05-09 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 ☐ TRANSITION REPORT PURSUANT TO
2025-03-28 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K
2024-11-08 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 ☐ TRANSITION REPORT PURSUANT
2024-08-09 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 ☐ TRANSITION REPORT PURSUANT TO S

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2025-05-15 14,961 43,393 34.48
2025-05-14 5,409 16,298 33.19
2025-05-13 6,190 28,876 21.44
2025-05-12 4,202 12,684 33.13

(click for more detail)

Similar Companies
ENLV – Enlivex Therapeutics Ltd. ENSC – Ensysce Biosciences, Inc.
ENTO – Entero Therapeutics, Inc. ENVB – Enveric Biosciences, Inc.
EPIX – ESSA Pharma Inc.


Financial data and stock pages provided by
Fintel.io